DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- 22 December 2011
- journal article
- review article
- Published by Elsevier BV in Diabetes & Metabolism
- Vol. 38 (2), 89-101
- https://doi.org/10.1016/j.diabet.2011.11.001
Abstract
No abstract availableKeywords
This publication has 95 references indexed in Scilit:
- A review of gliptins in 2011Expert Opinion on Pharmacotherapy, 2011
- Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetesAnnales d'Endocrinologie, 2011
- Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trialsDiabetes/Metabolism Research and Reviews, 2011
- Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug CombinationsAnnals of Internal Medicine, 2011
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 DiabetesPharmacology, 2010
- Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 DiabetesJAMA, 2010
- Addition of incretin therapy to metformin in type 2 diabetesThe Lancet, 2010
- Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapyDiabetologia, 2008
- New Drugs for Type 2 Diabetes MellitusDrugs, 2008